PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Key Highlights
- ➤GlyphAgo bioavailability increased 6.8-fold versus unmodified agomelatine
- ➤GlyphAgo PK variability was 10-fold lower than unmodified agomelatine
- ➤Phase 1 trial enrolled 174 healthy volunteers and showed no food effect
- ➤Seaport initiated Phase 2a trial; topline results expected in early 2028
- ➤Phase 2/3 GlyphAgo trial planned for generalized anxiety disorder in first-half 2027
Expert Statements
Daniel Bonner, Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“The data presented at ECNP provide important clinical validation that our Glyph™ platform can meaningfully improve the pharmacokinetic profile of medicines historically limited by high first-pass liver metabolism.”
Daniel Bonner, Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“The increased exposure and markedly reduced inter-individual variability observed in the Phase 1 program are particularly compelling.”
Daniel Bonner, Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“More predictable drug exposure may translate into more consistent clinical outcomes for patients, further supporting the development of GlyphAgo as a potential treatment for generalized anxiety disorder.”
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed pharmacokinetic (PK) analyses supporting previously reported topline results and reinforcing GlyphAgo's differentiated profile.
Get started
Create a free account to read the full story.